Lutrate Depot Kit
Product Images NDC 83831-134

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Lutrate Depot (NDC 83831-134). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avyxa Pharma, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton (Carton)

Carton packaging label for Lutrate Depot 22.5 mg kit containing leuprolide acetate for depot suspension. The label describes the product as for intramuscular injection and includes manufacturer Avyxa Pharma, LLC, with storage instructions and contents listed. The package is white with purple accents and barcode.*

FDA Label Image

Fig 1.jpg (Figure01)

An instructional diagram showing components of the LUTRATE DEPOT kit, including a syringe with plunger rod, backstop, and barrel containing a diluent vial for reconstitution, connected via a vial adapter to a needle. A separate LUTRATE DEPOT vial with a flip-off button is also shown.*

FDA Label Image

Fig 10.jpg (Figure010)

An instructional illustration showing a hand wearing a glove holding a syringe at a 90-degree angle to the surface of the upper buttock area of a simplified human body outline, indicating the proper technique for intramuscular injection.*

FDA Label Image

Fig 2.jpg (Figure02)

An instructional illustration demonstrating the preparation of LUTRATE DEPOT kit by Avyxa Pharma, LLC. The images show gloved hands removing the cap from a vial of leuprolide acetate and then preparing a syringe presumably for administration, emphasizing aseptic technique and proper handling of the drug kit components.*

FDA Label Image

Fig 3.jpg (Figure03)

Lutrate Depot kit containing a vial of leuprolide acetate for depot suspension, labeled with 22.5 mg strength. The vial is partially visible beneath a clear plastic blister packaging with a gloved hand holding it. The labeler is Avyxa Pharma, LLC.*

FDA Label Image

Fig 4.jpg (Figure04)

Instructional illustration showing two steps of preparing LUTRATE DEPOT leuprolide acetate kit components for use. The left image depicts a gloved hand twisting to unlock a syringe or vial cap. The right image shows a gloved hand twisting to attach a syringe to a vial or device. Arrows indicate the direction for twisting motions.*

FDA Label Image

Fig 5.jpg (Figure05)

Illustration showing gloved hands preparing a Leuprolide Acetate injection using a vial labeled Lutrate Depot 22.5 mg and a syringe prefilled with 2 mL diluent (0.8% w/v) for reconstitution of Leuprolide. The image demonstrates the mixing step in the drug preparation process.*

FDA Label Image

Ifig 6.jpg (Figure06)

An instructional diagram showing gloved hands handling and preparing a Lutrate Depot kit vial with a syringe attached. The vial label indicates Lutrate Depot (leuprolide acetate for depot suspension) with a strength of 22.5 mg and storage instructions at 20 to 25°C (68°F to 77°F). The images demonstrate steps in medication preparation or administration.*

FDA Label Image

Fig 7.jpg (Figure07)

Illustration showing a gloved person preparing an injection by mixing a vial with a syringe labeled as containing 2 mL of mannitol solution (0.8% w/v) diluent for reconstitution of leuprolide, associated with the LUTRATE DEPOT kit containing leuprolide acetate.*

FDA Label Image

Fig 8.jpg (Figure08)

Illustration showing a gloved hand drawing solution from a vial labeled LUTRATE DEPOT (leuprolide acetate) using a syringe. Another gloved hand holds the syringe and vial, demonstrating drug preparation for administration.*

FDA Label Image

Fig 9.jpg (Figure09)

LUTRATE DEPOT kit by Avyxa Pharma, LLC showing a close-up of a gloved hand holding a prefilled syringe labeled with leuprolide acetate injection. The syringe includes a needle and visible labeling on the barrel. Dosage and concentration details are partially visible on the syringe label.*

FDA Label Image

Figure 1 (Figure1)

A line graph showing testosterone concentration (ng/dL) over time (days) up to 168 days. The graph displays an initial high concentration around 400-600 ng/dL that sharply drops to below 100 ng/dL by day 14 and remains low and relatively stable with minor fluctuations through day 168.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of the active ingredient leuprolide acetate, depicting its peptide sequence with labeled amino acid residues and the acetate component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.